Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial by Folegatti, PM, Harrison, K, Lopez, KR, Tilley, MW, Lopez-Camacho, C, Kim, YC, Preciado-Llanes, L, Rossi, SL, Poulton, I, Jenkin, D, Datoo, M, Themistocleous, Y, Lawrie, A, Roberts, R, Ewer, K, Berrie, E, Hill, A, Reyes-Sandoval, A

Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults by Coughlan, L, Sridhar, S, Payne, R, Edmans, E, Milicic, A, Venkatraman, N, Lugonja, B, Clifton, L, Qi, C, McMichael, A, Folegatti, PM, Lawrie, AM, Roberts, R, de Graaf, H, Sukhtankar, P, Faust, SN, Lewis, DJM, Lambe, T, Hill, AVS, Gilbert, SC

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 t... by Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.

High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant by Venkatraman, N, Bowyer, G, Edwards, NJ, Griffiths, O, Powlson, J, Silman, D, Morter, R, Folegatti, PM, Minassian, AM, Poulton, ID, Collins, K, Brod, F, Angell-Manning, P, Berrie, E, Brendish, N, Glenn, G, Fries, L, Baum, J, Blagborough, AM, Roberts, R, Lawrie, AM, Lewis, DJ, Faust, SN, Gilbert, S, Ewer, KJ, Hill, AV

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: safety and parasite growth dynamics by Salkeld, J, Themistocleous, Y, Barrett, JR, Mitton, CH, Rawlinson, TA, Payne, RO, Hou, MM, Khozoee, B, Edwards, NJ, Nielsen, CM, Sandoval, DM, Bach, FA, Nahrendorf, W, Ramon, RL, Baker, M, Ramos-Lopez, F, Folegatti, PM, Quinkert, D, Ellis, KJ, Poulton, ID, Lawrie, AM, Cho, J-S, Nugent, FL, Spence, PJ, Silk, SE, Draper, SJ, Minassian, AM

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil by Clemens, SAC, Folegatti, PM, Emary, KRW, Weckx, LY, Ratcliff, J, Bibi, S, Verena De Almeida Mendes, A, Milan, EP, Pitella, A, Schwarzbold, AV, Sprinz, E, Aley, PK, Bonsall, D, Fraser, C, Fuskova, M, Gilbert, SC, Jenkin, D, Kelly, S, Kerridge, S, Lambe, T, Marchevsky, NG, Mujadidi, YF, Plested, E, Ramasamy, MN, Simmonds, P, Golubchik, T, Voysey, M, Pollard, AJ

Highly sensitive lineage discrimination of SARS-CoV-2 variants through allele-specific probe PCR by Ratcliff, J, Al-Beidh, F, Bibi, S, Bonsall, D, Costa Clemens, SA, Estcourt, L, Evans, A, Fish, M, Folegatti, PM, Gordon, AC, Jay, C, Jennings, A, Laing, E, Lambe, T, MacIntyre-Cockett, G, Menon, D, Mouncey, PR, Nguyen, D, Pollard, AJ, Ramasamy, MN, Roberts, DJ, Rowan, KM, Rynne, J, Shankar-Hari, M, Williams, S, Harvala, H, Golubchik, T, Simmonds, P

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 t... by Folegatti, PM, Bittaye, M, Flaxman, A, Lopez, FR, Bellamy, D, Kupke, A, Mair, C, Makinson, R, Sheridan, J, Rohde, C, Halwe, S, Jeong, Y, Park, Y-S, Kim, J-O, Song, M, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshal, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Becker, S, Lambe, T, Hill, A, Ewer, K, Gilbert, S

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four random... by Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial by Emary, KRW, Golubchik, T, Aley, PK, Angus, B, Bibi, S, Bonsall, D, Cicconi, P, Clutterbuck, EA, Dold, C, Douglas, AD, Ewer, KJ, Flaxman, AL, Feng, S, Folegatti, PM, Fuskova, M, Green, CM, Green, CA, Greenland, M, Jenkin, D, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, YF, Phillips, DJ, Plested, E, Robinson, H, Song, R, Snape, MD, Hill, AVS, Lambe, T, Gilbert, SC, Voysey, M, Ramasamy, MN, Pollard, AJ, Et al.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial by Folegatti, PM, Ewer, KJ, Aley, PK, Angus, B, Becker, S, Belij-Rammerstorfer, S, Bellamy, D, Bibi, S, Bittaye, M, Clutterbuck, EA, Dold, C, Faust, SN, Finn, A, Flaxman, AL, Hallis, B, Heath, P, Jenkin, D, Lazarus, R, Makinson, R, Minassian, AM, Pollock, KM, Ramasamy, M, Robinson, H, Snape, M, Tarrant, R, Voysey, M, Green, C, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ, Oxford COVID Vaccine Trial Group

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) by Flaxman, A, Marchevsky, NG, Jenkin, D, Aboagye, J, Aley, PK, Angus, B, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Cicconi, P, Clutterbuck, EA, Davies, S, Dejnirattisai, W, Dold, C, Ewer, KJ, Folegatti, PM, Fowler, J, Hill, AVS, Kerridge, S, Minassian, AM, Mongkolsapaya, J, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Sheehan, E, Smith, H, Snape, MD, Song, R, Woods, D, Screaton, G, Gilbert, SC, Voysey, M, Pollard, AJ, Lambe, T

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials by Voysey, M, Flaxman, A, Aboagye, J, Aley, PK, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Charlton, S, Clutterbuck, EA, Davies, S, Dold, C, Edwards, NJ, Ewer, K, Faust, SN, Folegatti, PM, Fowler, J, Gilbride, C, Gilbert, SC, Godfrey, L, Hallis, B, Humphries, HE, Jenkin, D, Kerridge, S, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Snape, MD, Song, R, Thomas, KM, Ulaszewska, M, Woods, D, Wright, D, Pollard, AJ, Lambe, T

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK by Voysey, M, Clemens, SAC, Madhi, SA, Weckx, LY, Folegatti, PM, Aley, PK, Angus, B, Baillie, VL, Barnabas, SL, Bhorat, QE, Bibi, S, Briner, C, Cicconi, P, Collins, AM, Colin-Jones, R, Cutland, CL, Darton, TC, Dheda, K, Duncan, CJA, Emary, KRW, Ewer, KJ, Fairlie, L, Faust, SN, Feng, S, Ferreira, DM, Finn, A, Goodman, AL, Green, CM, Green, CA, Heath, PT, Hill, C, Hill, H, Hirsch, I, Hodgson, SHC, Izu, A, Jackson, S, Jenkin, D, Joe, CCD, Kerridge, S, Koen, A, Kwatra, G, Lazarus, R, Lawrie, AM, Lelliott, A, Libri, V, Lillie, PJ, Mallory, R, Mendes, AVA, Milan, EP, Minassian, AM, Lambe, T, Pollard, AJ

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses by Barrett, J, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD, Green, CM, Hill, AVS, Lambe, T, Pollard, AJ

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial by Ramasamy, MN, Minassian, AM, Ewer, KJ, Flaxman, AL, Folegatti, PM, Owens, DR, Voysey, M, Aley, PK, Angus, B, Babbage, G, Belij-Rammerstorfer, S, Berry, L, Bibi, S, Bittaye, M, Cathie, K, Chappell, H, Charlton, S, Cicconi, P, Clutterbuck, EA, Colin-Jones, R, Dold, C, Emary, KRW, Fedosyuk, S, Fuskova, M, Gbesemete, D, Green, C, Hallis, B, Hou, MM, Jenkin, D, Joe, CCD, Kelly, EJ, Kerridge, S, Lawrie, AM, Lelliott, A, Lwin, MN, Makinson, R, Marchevsky, NG, Mujadidi, Y, Munro, APS, Pacurar, M, Plested, E, Rand, J, Rawlinson, T, Rhead, S, Robinson, H, Ritchie, AJ, Ross-Russell, AL, Saich, S, Singh, N, Pollard, AJ, Oxford COVID Vaccine Trial Group

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire. by Swanson, PA, Padilla, M, Hoyland, W, McGlinchey, K, Fields, PA, Bibi, S, Faust, SN, McDermott, AB, Snape, MD, Voysey, M, Lambe, T, Pollard, AJ, Durham, NM, Kelly, EJ, Adlou, S, Aley, PK, Angus, B, Anslow, R, Baker, P, Bansal, H, Beveridge, A, Bridges-Webb, A, Ching, S, Cicconi, P, Clutterbuck, EA, Collins, AM, Darton, TC, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Ewer, KJ, Felle, S, Ferreira, DM, Folegatti, PM, Fuskova, M, Gaudinski, M, Gilbert, SC, Goodman, AL, Gordon, I, Green, CA, Harbolick, E, Hayes, S, Hill, AVS, Hill, H, Jenkin, D, Jepson, BM, Kasanyinga, M, Libri, V, Lillie, PJ, McGregor, AC

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV by Ogbe, A, Pace, M, Bittaye, M, Tipoe, T, Adele, S, Alagaratnam, J, Aley, PK, Ansari, MA, Bara, A, Broadhead, S, Brown, A, Brown, H, Cappuccini, F, Cinardo, P, Dejnirattisai, W, Ewer, K, Fok, H, Folegatti, PM, Fowler, J, Godfrey, L, Goodman, AL, Jackson, B, Jenkin, D, Jones, M, Longet, S, Makinson, RA, Marchevsky, NG, Mathew, M, Mazzella, A, Mujadidi, YF, Parolini, L, Petersen, C, Plested, E, Pollock, K, Rajeswaran, T, Ramasamy, MN, Rhead, S, Robinson, H, Robinson, N, Sanders, H, Serrano Fandos, S, Tipton, T, Waters, A, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Screaton, GR, Winston, A, Gilbert, SC, Pollard, AJ, Lambe, T, Frater, J

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination by Minassian, AM, Silk, SE, Barrett, JR, Nielsen, CM, Miura, K, Diouf, A, Loos, C, Fallon, JK, Michell, AR, White, MT, Edwards, NJ, Poulton, ID, Mitton, CH, Payne, RO, Marks, M, Maxwell-Scott, H, Querol-Rubiera, A, Bisnauthsing, K, Batra, R, Ogrina, T, Brendish, NJ, Themistocleous, Y, Rawlinson, TA, Ellis, KJ, Quinkert, D, Baker, M, Lopez Ramon, R, Ramos Lopez, F, Barfod, L, Folegatti, PM, Silman, D, Datoo, M, Taylor, IJ, Jin, J, Pulido, D, Douglas, AD, de Jongh, WA, Smith, R, Berrie, E, Noe, AR, Diggs, CL, Soisson, LA, Ashfield, R, Faust, SN, Goodman, AL, Lawrie, AM, Nugent, FL, Alter, G, Long, CA, Draper, SJ